Vivos Announces Release of OSA Treatment Results in European Pediatric Journal

Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a leading proprietary non-invasive treatment company for obstructive sleep apnea (OSA), announced that the European Journal of Pediatrics has published results related to their treatment. GlobeNewswire

Impact Analysis

The publication of clinical results in a reputable journal like the European Journal of Pediatrics represents a significant milestone for Vivos Therapeutics. First-order effects include potential increased credibility and visibility in the medical community, which could lead to enhanced adoption of their treatment methods. It may expand their market reach, particularly in pediatric care settings, and strengthen their position against competitors who offer similar treatments. Second-order effects could involve influencing peer companies and industry standards in sleep apnea treatments, possibly encouraging cooperation or comparison. Investment opportunities may arise from Vivos Therapeutics’ reinforced market position, including considerations in options strategies targeting potential growth due to increased adoption and validation. However, risks include the dependence on continuous clinical validation and keeping pace with evolving medical standards. GlobeNewswire+ 2